Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

RealTalk MS

RealTalk MS artwork

Episode 473: The National MS Society -- A CEO Briefing with Dr. Tim Coetzee

Sep 21, 202639 minAudio
ShareXLinkedInFacebookWhatsAppEmail

RealTalk MS is celebrating our ninth anniversary, and we're marking the milestone with a special guest! Dr. Tim Coetzee, President and CEO of the National MS Society, returns to the show for a candid, forward-looking conversation about why today represents one of the most promising moments for advancing MS research and transforming clinical care. We're taking a hard look at the game-changers on the horizon: what it will take to shorten the diagnostic journey from years down to mere hours, why it's time to retire outdated disease labels in favor of true precision medicine, and the surprising science behind testing GLP-1s for neuroprotection. From unlocking massive clinical data sets to fighting for research dollars on Capitol Hill, Tim pulls back the curtain on the Society's strategic plan to end MS once and for all. Pop in your earbuds and join us in celebrating nine years of community and conversation! We have a lot to talk about! Are you ready for RealTalk MS??! This Week: Dr. Tim Coetzee briefs us on the National MS Society's strategic priorities and shares his vision of the future of MS care :18 Download the new RealTalk MS app for your iOS and Android smartphone and tablet 1:56 We gave the RealTalk MS website a glow-up! 2:37 Check your congressional representative's grade in the Congressional Healthcare Access Report Card 3:07 Dr. Tim Coetzee discusses the MS Society's strategic priorities and shares his vision of the future of MS care 3:46 Share this episode 37:04 Next week 37:24 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/473 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes at www.RealTalkMS.com REGISTER: ECTRIMS Patient Community Day 2026 https://ectrimspatientcommunity.eu DOWNLOAD: The New RealTalk MS App iOS: https://apps.apple.com/us/app/realtalk-ms/id6769516594 Android: https://play.google.com/store/apps/details?id=com.realtalkms.app&pcampaignid=web_share JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on X, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 473 Guest: Dr. Tim Coetzee Privacy Policy

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

JonIt's September 22nd, and we have something kind of special to talk about today. Nine years ago this week, I launched this podcast with a single clear mission. To cut through the noise, break down all the scientific jargon, and bring the latest in MS research, clinical care, and advocacy directly to the people who need it most, in plain, easy-to-understand English. Over hundreds of episodes, we've covered groundbreaking clinical trials, we've tracked major legislative wins and losses in our nation's capital,

Jonand shared conversations with the world's leading neurologists and MS researchers. But none of that happens in a vacuum. It happens because of a global community dedicated to changing what it means to live with multiple sclerosis. So I'd like to say thank you to every one of the hundreds of scientists and clinicians who have taken time out of what I know are incredibly busy schedules to talk with me and share their work with you. But most of all, I want to thank each of you for making Real Talk MS the most

Jonlistened-to podcast for the MS community. Whether you're a longtime listener or you just found Real Talk today, thank you for listening, and thank you for making this podcast a real conversation. I respond to every email and voicemail I receive, And it's your suggestions that really drive future episodes of the podcast. So from the bottom of my heart, thank you for being part of our listener community. To mark our ninth anniversary, I have some special announcements.

JonFirst, today we're releasing the Real Talk MS app for your iOS or Android smartphone. The app makes staying informed about the latest developments in MS research and care easy. The Real Talk MS app will automatically download the latest episode of the podcast. You'll be able to save your favorite episodes, and it has a great search function. You know, with close to 500 episodes, you need a great search function. And I'll be sharing bonus content that will only be available on the app.

JonYou can download the Real Talk MS app in the Apple App Store and the Google Play Store, and you'll find those links in today's show notes. I'll also invite you to visit the Real Talk MS website. We've given it a major glow up, and I can't wait for you to check it out. You'll find all our past episodes, the independent special series we produced, like Real Talk MS clinical trials and the MS caregiver conundrum. There's video interviews, coverage from all the major MS research conferences,

Jonand something I'm really excited about, but it's only going to be around for the next 50 days. Heading into the midterm elections in the United States, I think it's important for you to know how your congressional representatives and senators voted on major legislation impacting access to health care. So be sure to check out our Congressional Health Care Access Report Card. All you have to do is enter your state and you'll see how well your congressional representatives and senators did when it came to supporting the health care

Jonissues that affect you and your family. It's an easy way to help you make an informed decision when you cast your vote. You'll find all this at the new and improved realtalkms.com. You know, I wanted to make sure we had a special guest join me for our ninth anniversary. So I invited an old friend of the podcast who first joined me in episode number four and has returned several times over the years. So I'm devoting this entire episode to my conversation with someone who,

Jonthroughout his decades-long career at the National MS Society has truly been a difference maker for the global MS community. The president and CEO of the National Multiple Sclerosis Society, Dr. Tim Cutsey. And in a moment, we'll get to my conversation with Tim. Dr. Tim Kutzee is the president and CEO of the National MS Society, and I couldn't think of a better guest to have join me on the ninth anniversary of Real Talk MS.

JonWelcome back to the podcast, Tim.

Dr. Tim CoetzeeJon, it is great to be with you. I didn't realize we were talking about the ninth anniversary. You're just reminding me that you and I spoke very early on in that early season. Thanks for reminding me that I'm nine years older. Appreciate that, John.

JonI'd like to think of it as you being nine years better,

Dr. Tim CoetzeeBut to each their own. I'll take that. You'll be very kind. Thank you.

JonThis past year, we've seen the society adopt a new strategic plan centered around intervening at critical moments across an individual's MS journey to reduce their fear and feelings of isolation while expanding their sense of empowerment. What sort of inputs shape these priorities and what does this shift look like in day-to-day operations?

Dr. Tim CoetzeeThat's a great question and maybe I can step back and first of all thank you for the opportunity to join you today and before getting to your question really, get at maybe the moment we're in so I think that. It's not overstating things to say that we're in, I think, what is one of the most promising periods in the history of MS. And as you say, our focus as an organization, this is our 80th anniversary of our founding by Sylvia Lowry. And our focus is evolving from helping manage a disease that we didn't fully understand to one where,

Dr. Tim Coetzeeit's really a completely different era, where it's, we've got a research community that's focused, we've got incredible insights around biology, more treatments than ever. An incredible amount of innovation, which is what's also shaping the focus of the National Mass Society going forward, as your question alludes to. And my focus, our focus, isn't just about faster science. That is certainly true, but it's ensuring that when you have that faster accelerated science that leads to innovations, that those innovations get to the person

Dr. Tim Coetzeewho needs them, that they can access their care, they have the support they need, and, that gets us to what I think, I believe we can confidently say is seeing on the horizon, truly seeing on the horizon, not over the horizon, the notion that we can end MS, which is what really is what animates, my work as the CEO of the National MS Society. So maybe if I were to step back, I would say that the inputs were looking around at the world and asking the question, if we want to end MS.

Dr. Tim CoetzeeWhat would be the attributes of that world? And what would we need in order to get to that world? And for me, I have these four pillars that have anchored how we think about that world. And that world is a person can be diagnosed in hours rather than the months or years that has characterized things. Often, that person can get the right treatment at the right time for wherever they are in their MS journey. They can have the support and guidance of a community around them.

Dr. Tim CoetzeeAnd then the last pillar being that this MS diagnosis isn't anything that they fear because cures exist to that. And what we've been doing is looking at the world, understanding it, thinking at these pillars, and then organizing our work, around this kind of transformational change, looking at great outcomes today while we pursue the cures for tomorrow, moving beyond just managing the disease, but to truly changing lives and changing what it means to live with MS,

Dr. Tim Coetzeeboth now and the present and the future.

JonWe've learned that early intervention makes a real difference in long-term quality of life. And a major goal of the strategic plan is shortening the diagnostic timeline from months or years down to hours or days. Are there initiatives underway to equip primary care providers and general neurologists to recognize clues for MS, like early-stage biomarkers or even prodromal signals?

Dr. Tim CoetzeeYeah, so the short answer is yes. That's part of our agenda. And I will say, we have seen that getting the diagnosis is getting faster. So it used to be, could be three, four years on average for a person to go from that first symptom to a diagnosis. Now, depending on where you live, and if you're seeing an MS specialist, and you have a sort of an average case of how MS shows up, odds are you could be diagnosed within three to six months, which is much, much better than years, certainly.

Dr. Tim CoetzeeBut we got to do better than that. Weeks to hours is what I'm going for. But a key component in that in our healthcare system are those frontline providers. The primary care doctor that sees a person has come in because they've been dragging their leg or... The optician who sees someone who thinks that their eye problems are they need to do glasses, but it turns out that there's inflammation that they see. They are seeing the earliest clues of MS. And so part of the work that we're doing through our health care access team

Dr. Tim Coetzeeand other areas is leveling up the education, leveling up those early signs and symptoms so that people understand what are those earliest signs and symptoms that point to a person potentially having MS. And then beyond that is actually beginning to lay the groundwork for the other part of your question is are there ways that we could even pick up clues of MS before, the person is even got that clinic what we call a clinical symptom optic neuritis

Dr. Tim Coetzeeor potentially a loop you know having difficulty walking foot drop that's what your term prodrome means it's are there signs and symptoms of the disease before people even know it. And I actually think that we have the clues to that in the electronic medical records and in the, in the records from where people are seeing different doctors. And there's research to validate this research in Canada, here in the United States and in Germany. That has looked at groups of people who go on to get MS and compared them to

Dr. Tim Coetzeegroups of people who don't get MS. And if you look at the medical records of those people, you see that the people who develop MS start showing these signs. They go to the doctor more frequently. They're more frequently touching the healthcare system. And this is telling us that there's something going on. We don't quite know what the signal is other than they're seeing the doctor more, But that's a sign that something's happening. And I think long term, the ability for us to then be able to figure out data at scale, to be able to say, is there a signature that says that this person, something is going on?

Dr. Tim CoetzeeAnd the family practice doc says, you've got a few combinations here of things. Let's get you with a neurologist and do a screen and see what's happening. We're not at that world at this moment in time. But I think that's what we're driving towards through our strategic plan.

JonThe MS field is increasingly moving away from describing MS in rigid phenotype categories like relapsing-remitting or secondary-progressive MS in favor of understanding MS as a biological continuum driven at least partially by compartmentalized neuroinflammation and progression that occurs even in the absence of new lesions or relapses. How is a society aligning its research funding and clinical guidance with this emerging biological perspective?

Dr. Tim CoetzeeYeah, so that's a really good question. And I think that, let me underscore a few things, that this isn't just about changing words or labels. You got at it that what we want is to create a future where the care that a person is receiving is tailored to what is happening inside their particular body. The doctors would call this a precision medicine approach where, okay, let's try this treatment for this situation for this amount of time, and then we'll measure whether or not it's effective by ordering blood tests

Dr. Tim Coetzeeor images, and we'll see how it goes, and, if we need to tweak and tailor, we do this with another combination. Yeah. Other diseases, particularly cancer treatment, are seeing this really make a big difference. So we're aiming towards that in the context of MS. And as you said, our understanding of the biology that's underlying MS disease activity in a particular person has become very sophisticated. But the words we use to describe MS haven't evolved with that.

Dr. Tim CoetzeeAnd your audience knows about the terminology of relapsing remitting MS or relapsing MS as it's more frequently called now or primary progressive MS or secondary progressive MS. We've also got new terms like radiologically isolated syndrome creeping into the vocabulary. Words like smoldering MS are in the vocabulary. All of these are ways of. A clinician, which is why they were created, talking to the person in front of them saying, you've got MS, here's what it's appearing as,

Dr. Tim Coetzeehere's how we're going to manage the different aspects of the disease, and some of the labels apply in a certain context, and then a person might later on switch over to a different one. And it creates this illusion that somehow you've got different distinct types of MS. There isn't different types of MS. There's one disease, it's called multiple sclerosis. How it shows up is what varies within a person. And the thing is, as someone who lives in the world of words,

Dr. Tim Coetzeewords matter. Words are sticky. Descriptors are sticky. And the original descriptors, if I could just take each diversion into history, were created and were developed in the mid-1990s. This was work that was done by the National MS Society, because the doctors at the time were using a wide range of words to describe MS. And they were finding that one doctor described it one way, a different doctor could describe it another way. You had groups of doctors talking about it in the third or fourth way.

Dr. Tim CoetzeeAnd there was really a need, as we were entering an era, to design clinical trials and to do research to actually come up with a coherent. Paradigm or way of describing MS and not so much to create boxes, but to provide the vehicle by which a doctor could have a conversation with their patient. That was the original intent. And then they got adopted into approval statements by the FDA and designing clinical trials and a whole host of things downstream.

Dr. Tim CoetzeeAnd they have served their purpose in many respects when we did not understand the biology of the disease as we do today. But now, 30 years later, course descriptors were originally introduced in 1996, 30 years later, our understanding of MS is much deeper. The description by which we talk about the disease is much, much deeper. There are ways of understanding the treatment and how treatment affects disease per course and progression. And there's an evolution of diagnostic standards.

Dr. Tim CoetzeeOur words haven't kept pace. And so now we have a need to be able to evolve how a doctor talks to a particular patient about their disease. But there's also an important thing that has to be respected. And you know this, you and I have talked about this, is that words also do matter. And that if one is going to propose shifting from terminology that is very sticky, as the marketers would call it, things like relapsing or progressive, are sticky terms.

Dr. Tim CoetzeeIf you're going to say, we're going to not use those, you've got to replace them with something else that is just as sticky, and also. Understand what are the implications for the people living with MS who organized, everything according to this terminology. And it is really important to me that when we talk about evolving our language, we do it with an understanding of what will it mean for the person living with the disease? What will it mean for their family to introduce this and to have a very methodical

Dr. Tim Coetzeeapproach that takes us towards what we need, but also brings us back and anchors to the person at the center, right? So those are some of what we're doing. And I'll say the National Mass Society is very involved with driving that work internationally, bringing the community together. But at the end of the day, we're about people. And this is about how it affects people.

JonYou know, when it comes to updating the way that MS is described, it's something that's going to impact a lot of major stakeholders, including the pharmaceutical companies, insurance companies, the FDA, Medicare, the clinician community, the research community, and the patient and caregiver community. Making a change affecting any one of those stakeholder groups would by itself be a heavy lift. So how do we get everyone to the table? And what do you see as a National MS Society's role in this work?

Dr. Tim CoetzeeYeah. So I think, to your point, we need to have all of the interest holders at the table. Part of our work was to convene a working group that you were part of to really think through what would be the roadmap for change, what are the things that need to be preserved, what needs to change, how do we evolve towards this future work. And so we've had this group of leaders working together. We just published our latest paper that outlined a roadmap for evolving from where we are today to where we need to go. And now the next phase is to say, okay, we have this roadmap.

Dr. Tim CoetzeeNow we need to start convening the community, working together, identifying what's the first thing we would do, and then the second thing we would do, and then the third thing we would do, and understanding the implications for interest holders like the FDA, pharmaceutical companies, people affected by MS. And our ambition is to create a table where all of those voices and perspectives are reflected. And also helping foster the innovation needed to answer some of these questions. Because ideally, you'd like to have a series of easy to administer tests that

Dr. Tim Coetzeewould give you the data you need that can tell you, OK, a person is here and this is where they are on their journey. Let's try this you'd want to have another test that assesses things a little further on to give you a really holistic insight of what's happening inside the person. I'd love to tell you that we have those today. We have a couple. We don't. And so this is the kind of innovation that we, through the society and our collaborative partners, need to do is that when we see gaps, we start to foster the innovation needed in order to deliver that.

Dr. Tim CoetzeeAnd that's the work we're trying to do. It's like the International Progressive MS Alliance that I know you're very passionate about. It's hard work bringing lots of people to the table. It requires inordinate amounts of patience. Also, very frankly, it also needs money. It needs resources because at some point you need to start investing in the science, investing in the development, investing in the communications, and that all takes people and resources. And so that's also part of what we have to rally the community to say,

Dr. Tim Coetzeelet's make these investments.

JonProgressive MS remains an urgent unmet need. Are there updates from the International Progressive MS Alliance or recent experimental medicine trials that give you confidence that we're closing in on viable new therapies for myelin repair or neuroprotection?

Dr. Tim CoetzeeYeah, so great question. And as you say, progressive MS is near and dear to my heart, as I know it is to yours. I like to think about the moment we're in, as if you were to describe the first era of MS therapy development, it was always, it was focused very much on relapses, controlling information. But now our next generation needs to focus on progression, for sure, without question. And so that's where work like the Alliance and the MS organizations around it are really focused. And I will say, it's important that we take stock of the fact that we do have,

Dr. Tim Coetzeetreatments for progressive MS. We've got a couple that are approved for primary progressive MS. There's some excitement that there might be some additional ones on the horizon soon, potentially, that could be beneficial, that might be approved by the FDA soon. I know there's some that are already approved in Europe. And so we are making progress. And I often, when I get the question, what seems like in a very halting kind of progress, I will say the era of treating relapsing MS started with one treatment, beta-seron in 1993.

Dr. Tim CoetzeeAnd then we had successive treatment development after treatment development. So you got to start somewhere. We started with Ocrevus. We now have a few others on their way. So we're excited about that. And I think within the context of the Alliance, what we're continuing to focus in on is. What are the areas of unmet need? So you touched on one of the areas of unmet need of treating what we call neuroprotection, preserving the brain, preventing damage from happening. And we actually are excited that we're funding a clinical trial of a GLP-1 these

Dr. Tim Coetzeedays. Everybody knows what a GLP-1 is. GLP-1 and mRNA. Everyone seems to know what those two things are now. But it's a GLP-1 drug, not one of the ones that you see advertised, but another one. That was invented by another company. And we're funding a clinical trial to explore whether or not it has the ability to preserve and protect the brain. There has been biology that showed that, yes, GLP-1s work in the brain and that they're actually able to protect brain cells.

Dr. Tim CoetzeeAnd so we're actually evaluating that as part of our work within the context of the Progressive MS Alliance. So excited to share that. We're also exploring using different imaging tools to be able to identify how our treatment's working in the context of progressive MS. And then also importantly, using our platform to make resources available for the community to be able to accelerate research. And we recently were able to announce the establishment of what we call our Community Imaging Data Resource.

Dr. Tim CoetzeeAnd what this is, it's a unique collection, of MRI images and all the clinical data from the major MS clinical trials involving progressive MS, data from more than 14,000 people who participated in clinical trials. So an enormous resource because for each person, you have their MRI images, how they did on the treatment, all sorts of clinical information. It's a goldmine of data that can help us understand progression,

Dr. Tim Coetzeehelp us understand imaging, help us figure out if we apply AI, can we develop tools to predict how a person is doing. And we were able to use the convening power of the Progressive MS Alliance to bring all the people that held those data sets together to put them into one place and then to make them available freely to the community. So very excited by what that means. And I will say the Progressive MS Alliance isn't standing still. We're in the midst of identifying and refining our scientific strategies. So hopefully in about six or seven months, I can rejoin your show and share

Dr. Tim Coetzeea bit about the next set of directions for the Progressive MS Alliance.

JonAs we've seen evidence solidify around the role of the Epstein-Barr virus as a trigger for MS, how close are we to seeing viable EBV prevention trials? And what role is the society playing in advancing preventative science?

Dr. Tim CoetzeeYeah, I agree with you. I think EBV as a potential trigger for the disease is certainly something that the data has really gotten strong and persuasive around. And we have actually started to have conversation thinking around how would you do a clinical trial, potentially a vaccine against EBV that prevents MS. And the thing about EBV is, Epstein-Barr virus, is this virus, besides causing mono, infectious mononucleosis, which college kids and soldiers and other people get.

Dr. Tim CoetzeeWhich potentially that infection leaves one susceptible to MS, does other things. It causes some cancers. It has other impacts. So there is actually an interest in developing a vaccine against it because of its effect in these other areas. It's associated with a form of cancer called nasopharyngeal, cancer of the nasal passages. And so there is actually good reason and good interest around that. But the challenge around doing a trial of whether or not an EBV vaccine prevents

Dr. Tim Coetzeeonset of MS is you have to think about the time horizon. So if you were to give a vaccine to someone, say, before they go to college, so at the age of 18 or so, and then you'd have to follow them over a really long time to see, do they get MS? Don't they get MS? You have to do that on a sufficiently large enough population of people. If you do it the conventional way to be able to understand what matters. So that's a pretty daunting proposition, I would say. Even if you could figure out how to make a vaccine, figure out how to capture

Dr. Tim Coetzeeit, because that's the other tricky part for your audience is that building a vaccine requires a factory and a company that's prepared to do it. So there's some logistical hurdles that need to be overcome there. But let's say you figure out those logistical hurdles. There's still the design of the trial. And actually, my colleague, Bruce Bebo, our Chief Research and Medical Affairs Officer, partnered with the University of Washington School of Public Health to actually work on this. We published a paper that outlined our thinking around what would be required

Dr. Tim Coetzeeto do a clinical trial of a preventative strategy. And the good news is that there are ways to enrich it so that you can find the potential people who have higher susceptibility and follow them over time. But it laid the groundwork for thinking around this. And the good news is that I know that there are different, larger companies in the sector that have an interest in vaccine strategies that are turning their attention to that. I won't name drop because these programs come and go, but I will say that there is considerable interest and we are very supportive around thinking through that with people.

Dr. Tim CoetzeeBecause I think it would be remarkable if we could figure out how to prevent the onset of MS using a vaccine strategy.

JonBeyond disease-modifying therapies, where does research on non-pharmacological interventions like exercise, diet, cognitive rehabilitation, and mental health, where do they fit into the society's strategic vision?

Dr. Tim CoetzeeSo all an important part of our portfolio because, and I think this is one of the things that our approach to managing MS has evolved so much. We used to focus in on getting an early diagnosis, start a disease-modifying treatment, but things like diet, nutrition, exercise, comorbidities, mental health, we're all, yeah, those are some other things. Yeah, do them if you want, but there's not, wasn't necessarily a point of emphasis. Now, very much a point of emphasis. We know that nutrition is an important part

Dr. Tim Coetzeeof living well and ensuring that. Be able to be strong and healthy as one lives with MS. Addressing comorbidities such as smoking or other hypertension, other aspects that could also create illness in the body that could amplify, the challenges associated with MS. We also know that MS can have an impact on mental health and well-being. Depression and mental health comorbidities and mental health challenges are among the highest of the comorbidities and disease conditions that go alongside MS in the community.

Dr. Tim CoetzeeSo managing those is really critical and investing in research and to address all those is all part of our portfolio. I see it as just as essential to invest in that as it is to try to get at the cause and figuring out the new treatments for say things like myelin repair. And it's really vital that we continue to grow and sustain that. It is part of our work within the context of the Progressive MS Alliance has been to grow the number of researchers and develop a pipeline, as we call it, of people working in this area.

Dr. Tim CoetzeeSo it is a vital part, both of the science part of our equation, but also about how we support people through the journey of MS, because so many of these interventions, become really meaningful when a person can access them, being able to talk to a therapist, being able to participate in rehabilitative medicine. All of those are critical to our ability to approach the challenge of life with MS holistically, which is what I think we want for everyone.

JonHaving breakthrough therapies isn't helpful if patients can't access them. So what steps is a society taking to eliminate disparities in diagnosis and access to comprehensive specialty care across underserved and rural communities?

Dr. Tim CoetzeeYeah, so those are all part of an overarching agenda within our advocacy and healthcare access team. And it's part of our work to, one, highlight the challenges that people encounter in accessing their treatments or getting access to a doctor. So every year as part of our advocacy agenda, we're highlighting the importance of affordability, access to treatment. There's no point in having treatments if people can't access them or can't afford them, but they also need to be able to have access to doctors. And so we invest in training doctors to get MS specialists.

Dr. Tim CoetzeeOver the last few years, we've been partnering with a great partner, Genentech, on a project looking at neurology deserts and understanding what it looks like for MS to be delivered in rural settings and understanding, how do people in parts of America that don't necessarily have a neurologist as close to them as, say, in large or more urban areas, navigate this disease. And also understanding that sometimes you even can have care deserts within a highly dense urban area.

Dr. Tim CoetzeeYou could have no neurologists within an hour of someone, or it could be two hours by multiple to get to a doctor, which can exhaust people. And so understanding the geographic landscape of where are the doctors, how long does it take for people to get them has been part of our work to really then begin to hone in on. How does one address the systemic challenges that get in the way? And it's not as simple as saying more doctors shouldn't go to rural America. That is, yes, a desirable goal.

Dr. Tim CoetzeeChallenge we have is we're not producing enough doctors in this country where people aren't choosing neurology as a specialty in this country. Or it's not just enough to put an MS specialist inside a system. That MS specialist actually needs a supportive system that will support all the work they need. They need the MRIs, they need the nurses, they need to have the facilities to do infusions of the treatments. It actually takes an ecosystem to have an MS center. It's not just about having a doctor. And so I think all of those are part of a holistic approach that we're taking

Dr. Tim Coetzeethrough our advocacy and healthcare access work and our medical affairs works to really understand the journey, understand, how systems need to evolve to get people better care.

JonSpeaking of advocacy, in this era of tight and unpredictable federal budgets, how is the society working to ensure robust funding for the National Institutes of Health and the MS Research Program at the Department of Defense?

Dr. Tim CoetzeeYou're right. And there was some unpredictability last year when the MS Research Program was unilaterally cut as part of work with part of one of the legislation. And good news is we were able to restore that back to $15 million this year. So that was a real win for all of our advocates. And we're working very closely now with congressional champions to be able to do that. And I would say, John, it is the same tried and true work. It's about relationships, relationships, relationships. And so our advocacy team is building relationships with the key influential legislators on Congress up on Capitol Hill,

Dr. Tim Coetzeebut also our activists out in the field, engaging with their representatives to let them know how important it is to support MS. And it is a long game that we're playing here, and it's not like you get a win one year and you can just sit back. Being engaged in the political process, being engaged in keeping your priorities front and center is something you have to come back to every single year, every single month, because it's too easy. The minute you get complacent, something in our environment will come in and obscure it.

Dr. Tim CoetzeeAnd so we keep telling the stories, keep highlighting people, keep building relationships so that we can ensure that the agenda for solving MS is high on that over legislators. But also importantly, something that I'm really passionate about is keeping the agenda for the importance of discovery science, the blue sky work that NIH makes possible is so critical. So many of the advances that we take for granted today in medical care,

Dr. Tim Coetzeehad their origin in research that seemed a bit obscure, but led to a breakthrough that then had a transformational effect in care. And that's the challenge. You don't know what the thing you invest in today might be that transformational thing for the future. And that's why it's really important that we sustain NIH, that some of that blue sky innovation discovery work can make it possible and can become part of the future. You know, today's investments become tomorrow's cures. It's really that simple.

JonTim, when you look across the research pipeline, clinical advances, and community resources over the next three to five years, what gives you the greatest hope for what an MS diagnosis will look like in the future?

Dr. Tim CoetzeeYeah, so I think if we can develop some tools that can predict and can identify those earliest signs, let's say this person might be having MS, we can then get them into a doctor, get a specialist to look at them and diagnose, yes, you have MS or no, you don't, give you clarity, peace of mind. And then we can start talking about managing the disease over a lifespan. And this is where the good news is we have treatments today, but I believe we need to continue to focus on getting new,

Dr. Tim Coetzeebetter, effective treatments that can manage this disease over a lifetime, which are also highly safe and effective such that it brings MS down to not even being a noticeable part of their life. Now, what I'm talking about is very future-focused. We also can't lose sight of the fact that there are people living today who will not have the benefit of some of those incredible advances and MS has robbed them of so much. And this is where our supportive programs, other types of medical interventions,

Dr. Tim Coetzeerestorative interventions also need our focus. Because there are people living with MS today for whom the disease has taken so much. So we cannot lose sight of that as we push towards this future. But to me, those are all the part of the portfolio of the work of the National MS Society that I believe supporters like you and so many others make possible. Taking that holistic approach will also mean that we bring cures to everybody.

JonDr. Tim Kutze, I want to thank you for all the National MS Society does in supporting clinicians, funding research, and keeping people living with MS and their care partners at the center of all its work. And thanks so much for joining me to celebrate nine years of Real Talk MS.

Dr. Tim CoetzeeJon, thank you. It's great to be with you and your audience, and I look forward to getting with you again at year 10.

JonThat's going to wrap up this nine-year anniversary episode of Real Talk MS. Real Talk MS is powered by the National MS Society, and you can share this episode of the podcast by letting your friends or family members know that all they have to do is point their web browser at realtalkms.com slash 473. You'll find that link in today's show notes so you can easily copy and paste it right into an email or a text. Imagine for a moment that you're recently diagnosed with MS and your symptoms are quite mild.

JonBut you're a single mom, and you want to be responsible when it comes to planning for the future. And you worry that if your MS progresses and you develop mobility issues, the home you're living in won't really work for you. So you decide to build a house that will be 100% accessible, because if you wait until you need that kind of accommodation, well, it'll be too late to do anything about it. Oh, and by the way, you're not an architect, and you know virtually nothing about building a house.

JonWell, that's exactly where Sarah Timmerman found herself. So she launched the House That MS Built project. Next week, as we begin year 10 of Real Talk MS, we'll meet Sarah. She's a force, and you won't want to miss hearing her story. I'm Jon Strum. Thanks for listening. Stay safe and make healthy choices.

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Episode 482: Taking Your MS to Work? Tap Into the Power of an ERG with Chuck Edward

    Nov 16, 202635 minAudio

    Navigating a chronic illness at work often feels like walking a tightrope - balancing the fear of judgment against the need for support. This week, we're joined by Chuck Edward, a 30-year HR veteran and former Vice...

    Credit the people on this episode

  2. Episode 481: It's Time to Update the Way We Describe MS with Dr. Peter Calabresi

    Nov 9, 202631 minAudio

    The current clinical language used to describe multiple sclerosis hasn't kept pace with modern neuroscience - and clinging to outdated categories can stall treatment decisions, muddy research, and obscure what people...

    Credit the people on this episode

  3. Episode 480: MSToronto 2026 with Dr. Jeffrey Cohen and Dr. Robert Fox

    Nov 2, 202637 minAudio

    Our coverage of MSToronto 2026 continues this week with two important conversations. First, we'll hear from Dr. Jeffrey Cohen about the latest clinical findings on CAR-T cell therapy as a potential treatment for MS....

    Credit the people on this episode

  4. Episode 479: From MSToronto 2026 with Dr. Bruce Bebo and Kristine Werner Ozug

    Oct 29, 202646 minAudio

    Last week, about 8,000 MS researchers and clinicians arrived in Toronto, Canada, for MSToronto 2026, the joint meeting of the Americas Committee for Treatment and Research in MS and the European Committee for Treatment...

    Credit the people on this episode

  5. Episode 478: From MSToronto 2026 Patient Community Day with Professor Peter Feys and Karen Jacoby

    Oct 26, 202622 minAudio

    Welcome to a special episode of RealTalk MS and The ECTRIMS Podcast! MS Toronto 2026 concluded with the event we were most looking forward to -- Patient Community Day -- where some of the top MS experts in the world...

    Credit the people on this episode